Ketolides Market Growth Outlook Through 2024-2033

Overview and Scope
Ketolides are a class of antibiotics that belong to the macrolide group derived from erythromycin, a 14-membered macrolide, by substituting the cladinose sugar with a keto-group and attaching a cyclic carbamate group in the lactone ring. They prevent protein synthesis and prevent bacteria from producing vital proteins needed for maintenance and survival.

Sizing and Forecast
The ketolides market size has grown strongly in recent years. It will grow from $3.07 billion in 2023 to $3.22 billion in 2024 at a compound annual growth rate (CAGR) of 5.0%. The growth in the historic period can be attributed to increasing prevalence of infectious diseases, growing consumption of antibiotics, demand for effective and convenient treatments for infectious diseases, government initiatives.

The ketolides market size is expected to see steady growth in the next few years. It will grow to $3.82 billion in 2028 at a compound annual growth rate (CAGR) of 4.4%. The growth in the forecast period can be attributed to investments in research and development activities for ketolides, growing number of screening programs for infectious diseases, incremental healthcare spending. growing awareness of antimicrobial stewardship. Major trends in the forecast period include innovative treatments for infectious diseases, development of targeted therapies, advancements in diagnosis and treatment of infectious diseases, development of new ketolide formulations.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/ketolides-global-market-report

Segmentation & Regional Insights
The ketolides market covered in this report is segmented –

1) By Drug Type: Telithromycin; Cethromycin; Solithromycin
2) By Indication: Bronchitis; Pneumonia; Sinusitis; Tonsillitis Or Pharyngitis
3) By Microorganism: Streptococcus Pneumoniae; Haemophilus Influenzae; Moraxella Catarrhalis; Chlamydophila Pneumoniae; Mycoplasma Pneumoniae
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels

North America was the largest region in the ketolides market in 2023. The regions covered in ketolides market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12918&type=smp

Major Driver Impacting Market Growth
The increasing prevalence of infectious diseases is expected to propel the growth of the ketolides market going forward. Infectious diseases are illnesses caused by pathogens such as bacteria, viruses, fungi, or parasites that can spread from person to person, resulting in a wide range of symptoms and health complications. Tuberculosis is one type of infectious disease. Ketolides, which are used in treating infectious diseases, have been evaluated for their potential use in treating tuberculosis as they exhibit high levels of intracellular activity, which play a significant role in treating tuberculosis. For instance, in October 2022, according to the Global Tuberculosis Report published by the World Health Organization, a Switzerland-based global health agency, there were an expected 10.6 million tuberculosis (TB) cases worldwide in 2021, a 4.5% rise from 10.1 million cases in 2020. Therefore, the increasing prevalence of infectious diseases is driving the growth of the ketogenic market.

Key Industry Players
Major players in the ketolides market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, GSK PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Shionogi & Company Limited, Dr. Reddys Laboratories Ltd., Taisho Pharmaceutical Co. Ltd., Glenmark Pharmaceuticals Ltd., Zhejiang Yongtai Technology Co. Ltd., Corden Pharma GmbH, Optimer Pharmaceuticals Inc., Vivimed Labs Limited, Wockhardt Ltd., Advanced Life Sciences Holdings Inc.

The ketolides market report table of contents includes:

1. Executive Summary
2.Ketolides Market Characteristics
3.Ketolides Market Trends And Strategies
4.Ketolides Market analysis
5.Ketolides Market Size And Growth
6.Ketolides Segmentation
7.Ketolides Regional And Country Analysis
.
.
.
27. Ketolides Competitive Landscape And Company Profiles
28. Ketolides Key Mergers And Acquisitions
29. Ketolides Future Outlook and Potential Analysis

TOP MAJOR PLAYERS:

• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• Merck & Co. Inc.
• Bayer AG
• Novartis AG

Explore the trending research reports from TBRC:

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model